AGP Executive Report
Last update: 8 hours agoLiver Health: Taiwanese specialists are urging stronger action on fatty liver disease, which affects nearly 7 million people and about one-third of adults. Related liver cancer is rising even as hepatitis-linked cases decline. Cancer Care: China has approved Foresee Pharmaceuticals’ six-month CAMCEVI injection for adults with advanced prostate cancer; the Taiwan-based company licensed the drug to partner GenSci. Weight and Metabolism: Early human trials of Caliway Biopharmaceuticals’ experimental injection found a 12% reduction in visceral fat, which is linked to metabolic and heart risks. Healthy Aging: Taiwan recorded more than 26,000 reports of suspected elder abuse last year, up from 20,182 in 2022. Prevention: Taiwan marks 40 years of hepatitis B vaccination; the country met WHO targets for eliminating hepatitis C in 2025, five years ahead of schedule.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
